Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA

Posted: January 2, 2025 at 2:44 am

Hamilton, Bermuda, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB:CYTOF), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that its nanoparticle-based delivery platform was successfully tested also for circular mRNA. In vitro experiments demonstrated successful transfection of cells and significantly higher protein expression than with linear mRNA, based on which the Company has filed a provisional patent application with the United States Patent Office (USPTO). Altamira will start offering its platform to biotech and pharma companies for use with circular RNA under the CycloPhore™ label, complementing its offerings for siRNA (OligoPhore™) and mRNA (SemaPhore™).

Read more here:
Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA

Related Posts